News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx's Tenapanor Reduces Phosphorus Absorption and Protects against Vascular Calcification in Preclinical In Vivo Model of Chronic Kidney Disease
-- Data Published Online in the Journal of the American Society of Nephrology --
View HTML
Toggle Summary Ardelyx Reports Third Quarter 2014 Financial Results
Phase 2 Programs for Lead Product Candidate Tenapanor Continue to Advance in Multiple IndicationsArdelyx Updates Projected Timing of Results from Phase 2b Study in ESRD patients with HyperphosphatemiaConference Call and Webcast Today at 4:30 p.m. ET
View HTML
Toggle Summary Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014
FREMONT, Calif. , Oct. 30, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it will report third quarter 2014 financial results on Thursday, November 6, 2014 .
View HTML
Toggle Summary Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014
FREMONT, Calif. , Oct. 23, 2014 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Ardelyx , together with its development partner, AstraZeneca (NYSE:AZN, LON:AZN), will
View HTML
Toggle Summary Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients
-- Primary endpoint was met for 50 mg twice daily dosing --
View HTML
Toggle Summary Ardelyx Chief Scientific Officer, Dominique Charmot, Announces Retirement from the Company at Year-End
FREMONT, Calif. , Sept. 5, 2014 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Dominique Charmot , Ph.D., the Company's Chief Scientific Officer, has announced his
View HTML
Toggle Summary Ardelyx Reports Second Quarter 2014 Financial Results
Successfully Completed Initial Public Offering; Raised Net Proceeds of $61.2 MillionCompany Progressing Clinical Development of Lead Candidate, Tenapanor, In Three Ongoing Phase 2 Programs
View HTML
Toggle Summary Ardelyx to Present at the Wedbush 2014 Life Sciences Management Access Conference
FREMONT, Calif. , Aug. 5, 2014 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that Mike Raab , Ardelyx's President and Chief Executive Officer, is scheduled to present at the Wedbush 2014
View HTML
Toggle Summary Ardelyx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
FREMONT, Calif. , June 24, 2014 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the closing of its initial public offering of 4,928,900 shares of common stock at an initial public offering
View HTML
Toggle Summary Ardelyx Announces Pricing of its Initial Public Offering
FREMONT, California – June 18, 2014 – Ardelyx, Inc.,  a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the pricing of its initial public offering of 4,286,000 shares of common stock at a public offering price of $14.00
View HTML